Biogen and Alcyone Enter into a License Agreement for ThecaFlex DRx System to Treat Patients with Neurological Conditions
Shots:
- Under the terms of the agreement, Alcyone will receive $10M upfront & is eligible to receive up to $41M in development & commercial milestone. Biogen aims to improve the treatment experience for patients with neurological conditions
- Biogen & Alcyone will jointly collaborate for the clinical development of the ThecaFlex DRx System for ASO therapies whereas Alcyone will be responsible for its manufacturing & commercialization
- ThecaFlex DRx System is an implantable medical device developed for the subcutaneous delivery of ASO therapies into the intrathecal space for patients with a chronic neurological condition. Additionally, ThecaFlex DRx System is expected to be initially evaluated with Spinraza
Ref: Globenewswire | Image: Biogen
Related News:- Biogen Reports the US FDA’s Acceptance of Abbreviated BLA of BIIB800 (biosimilar, tocilizumab) for Rheumatoid Arthritis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
